杀伤细胞联合化疗治疗中晚期肺癌的效果及对免疫功能、B7H4蛋白水平的影响

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (41 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨杀伤细胞（CIK）联合化疗治疗中晚期肺癌的临床效果，并探讨其对患者免疫功能及B7H4 蛋白水平的影响。方法选取2017年5月～2019年4月上海市某医院肿瘤科收治的110 例中晚期肺癌患者为研究对象，依据双盲法分为联合组与化疗组，每组各55 例。化疗组实施化疗，联合组在化疗的基础上联合CIK 治疗，观察两组患者的疗效、治疗前后的免疫功能水平、癌胚抗原（CEA）及其B7H4 蛋白水平。结果联合组的总有效率高于化疗组，差异有统计学意义（P＜0.05）；两组患者治疗前的CD3+、CD4+、CD4+/CD8+、B7H4 蛋白、CEA 水平比较，差异均无统计学意义（P＞0.05）；联合组患者治疗后的CD3+、CD4+、CD4+/CD8+水平高于化疗组，B7H4 蛋白、CEA 水平低于化疗组，差异有统计学意义（P＜0.05）。结论 CIK 联合化疗应用于中晚期肺癌中具有一定的疗效，可通过下调患者的B7H4 蛋白水平显著提高其免疫功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄岚
	刘继斌

关键词 ：杀伤细胞, 化疗, 中晚期肺癌, 免疫功能, B7H4 蛋白

Abstract：Objectives To investigate the clinical effect of cytokine-induced killer (CIK) combined with chemotherapy in the treatment of middle and advanced lung cancer and the influence on immune function and B7H4 protein level.Methods A total of 110 patients with middle and advanced lung cancer admitted to the oncology department of a hospital in Shanghai from May 2017 to April 2019 were selected as the research objects. According to the double-blind method, they were divided into the combination group and the chemotherapy group, with 55 cases in each group. The chemotherapy group was treated with chemotherapy, and the combination group was treated with CIK based on chemotherapy. The curative effect, immune function level, carcinoembryonic antigen (CEA) and B7H4 protein levels before and after treatment between the two groups were observed. Results The total effective rate of the combined group was higher than that of the chemotherapy group, and the difference was statistically significant (P＜0.05). There were no significant differences in the levels of CD3+, CD4+, CD4+/CD8+, B7H4 protein and CEA between the two groups before treatment (P＞0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in the combined group were higher than those in the chemotherapy group, while the levels of B7H4 protein and CEA in the combined group were lower than those in the chemotherapy group, and the differences were statistically significant (P＜0.05). Conclusion CIK combined with chemotherapy in the treatment of middle and advanced lung cancer has certain curative effect, which can significantly improve the immune function of patients by down-regulating the level of B7H4 protein.

Key words： Cytokine-induced killer Chemotherapy Middle and advanced lung cancer Immune function B7H4 protein

引用本文:

黄岚；刘继斌. 杀伤细胞联合化疗治疗中晚期肺癌的效果及对免疫功能、B7H4蛋白水平的影响[J]. 中国当代医药, 2020, 27(28): 39-42.
HUANG Lan； LIU Ji-bin. Effect of cytokine-induced killer combined with chemotherapy in the treatment of middle and advanced lung cancer and its influence on immune function and B7H4 protein level. 中国当代医药, 2020, 27(28): 39-42.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I28/39

[1]	刘畅，赵晓珍，王中奇，等.肺岩宁方联合抗瘤增效方对中晚期肺腺癌患者化疗后癌因性疲乏、免疫功能及肿瘤标志物影响的临床研究[J].上海中医药杂志，2019，52（6）：49-53.
[2]	苏越，宋涛.心理干预对中晚期肺癌患者心理痛苦、行为功能及生活质量的影响[J].癌症进展，2019，17（4）：117-119.
[3]	童琳，丁宁，李佳旻，等.晚期肺癌患者胸腔积液上清液中肿瘤游离DNA 检测肿瘤突变负荷的研究[J].中华结核和呼吸杂志，2019，42（8）：596-601.
[5]	2015 版美国国立综合癌症网络（NccN）指南：非小细胞肺癌更新要点[J].实用心脑肺血管病杂志，2015，3（2）：55.
[6]	王蓉，郭伟，宋霞.血清癌胚抗原水平及表皮生长因子受体突变状态与晚期肺腺癌患者脑转移的关系[J].肿瘤研究与临床，2019，31（8）：556-559.
[8]	李晓黎，吴坤荣，尹影，等.奈达铂致肺癌患者骨髓抑制的危险因素研究[J].药物不良反应杂志，2020，22（4）：239-246.
[4]	Portan DV，Deligianni DD，Papanicolaou GC，et al.Combined Optimized Effect of a Highly Self-Organized Nanosubstrate and an Electric Field on Osteoblast Bone Cells Activity[J].Biomed Res Int，2019，21：7574635.
[7]	Mariglia J，Momin S，Coe IR，et al.Analysis of the cytotoxic effects of combined ultrasound，microbubble and nucleoside analog combinations on pancreatic cells in vitro[J].Ultrasonics，2018，9（89）：110-117.
[9]	Schmidt J，Appold S，Troost EGC.Impact of prophylactic cranial irradiation on overall survival of patients with advanced non-small-cell lung cancer[J].Strahlenther Onkol，2019，195（5）：453-456.
[10]	白馨雅，张金梦，孙洋，等.免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J].国际肿瘤学杂志，2019，46（8）：500-504.
[11]	刘玉娟.综合护理干预对中晚期肺癌患者生活质量的影响[J].西部中医药，2018，31（3）：116-119.
[12]	安青，吴燕波，李伟兵，等.补精解毒方联合化疗治疗老年中晚期非小细胞肺癌40 例[J].西部中医药，2018，31（10）：76-79.
[13]	Arbour KC，Jordan E，Kim HR，et al.Effects of co-occurring genomic alterations on outcomes in patients with KRASmutant non-small cell lung cancer[J].Clin Cancer Res，2018，24（2）：334-340.
[14]	王大权，毕楠，王绿化.局部晚期非小细胞肺癌放疗剂量提升研究进展[J].中华放射肿瘤学杂志，2019，28（10）：788-791.
[15]	张政，杨金红，荆晨晨，等.肺癌晚期患者死亡风险预测评分系统的构建及评价[J].护士进修杂志，2019，34（23）：2122-2126.
[16]	Lei CS，Hou YC，Pai MH，et al.Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells： in vitro and in vivo studies[J].J Nutr Biochem，2018，51：105-113.
[17]	李恩谦，张亚明，廖子静.中西医结合治疗中晚期肺癌患者的疗效[J].中国肿瘤临床与康复，2019，26（2）：80-82.
[18]	黄建清，何爱国，李亮，等.复方斑蝥胶囊联合GP 方案治疗中晚期肺鳞癌的临床效果[J].实用癌症杂志，2019，34（6）：968-970.
[19]	帕哈尔丁·白克热，黄伍奎，刘墨，等.CT 引导下125I 粒子植入联合化疗治疗中晚期肺癌的疗效及对血清肿瘤标志物影响[J].疑难病杂志，2019，18（8）：795-799.
[20]	苏宁，张贤兰，黄惠怡，等.晚期肺腺癌驱动基因分布及其一线治疗现状——单中心真实世界研究[J].实用医学杂志，2019，35（4）：537-540.